Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kent

Showing results (41-50 of 268) with videos related to

Pageof 27
Sort By:
JAMA Internal Medicine|October 4, 2016
Prediabetes Risk in Adult Americans According to a Risk TestSaeid Shahraz, Anastassios G Pittas, David M Kent
BMJ (Clinical Research Ed.)|December 12, 2018
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effectsDavid M Kent, Ewout Steyerberg, David van Klaveren
Journal of Medical Screening|December 1, 2021
All-cause mortality as the primary endpoint for the GRAIL/National Health Service England multi-cancer screening trialDavid Carr, David M Kent, H Gilbert Welch
International Journal of Epidemiology|November 20, 2016
Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidenceIssa J Dahabreh, Rodney Hayward, David M Kent
Stroke|February 8, 2003
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?David M Kent, Robin Ruthazer, Harry P Selker
Circulation. Cardiovascular Quality and Outcomes|April 23, 2015
All else being equal, men and women are still not the same: using risk models to understand gender disparities in careJessica K Paulus, Nilay D Shah, David M Kent
Lancet (London, England)|August 30, 2025
Estimating the benefits of personalised glycaemic controlDavid van Klaveren, Patrick W Serruys, David M Kent
JAMA|April 12, 2022
Treatment Effects in Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale-ReplyDavid M Kent, Jeffrey L Saver, David E Thaler
Annals of Internal Medicine|May 5, 2015
Pharmacologic interventions for knee osteoarthritisRaveendhara R Bannuru, David M Kent, Timothy E McAlindon
Trials|May 24, 2008
Competing risk and heterogeneity of treatment effect in clinical trialsDavid M Kent, Alawi Alsheikh-Ali, Rodney A Hayward
Pageof 27

Showing results (41-50 of 268) with videos related to

Sort By:
Pageof 27
JAMA Internal Medicine|October 4, 2016
Prediabetes Risk in Adult Americans According to a Risk TestSaeid Shahraz, Anastassios G Pittas, David M Kent
BMJ (Clinical Research Ed.)|December 12, 2018
Personalized evidence based medicine: predictive approaches to heterogeneous treatment effectsDavid M Kent, Ewout Steyerberg, David van Klaveren
Journal of Medical Screening|December 1, 2021
All-cause mortality as the primary endpoint for the GRAIL/National Health Service England multi-cancer screening trialDavid Carr, David M Kent, H Gilbert Welch
International Journal of Epidemiology|November 20, 2016
Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidenceIssa J Dahabreh, Rodney Hayward, David M Kent
Stroke|February 8, 2003
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?David M Kent, Robin Ruthazer, Harry P Selker
Circulation. Cardiovascular Quality and Outcomes|April 23, 2015
All else being equal, men and women are still not the same: using risk models to understand gender disparities in careJessica K Paulus, Nilay D Shah, David M Kent
Lancet (London, England)|August 30, 2025
Estimating the benefits of personalised glycaemic controlDavid van Klaveren, Patrick W Serruys, David M Kent
JAMA|April 12, 2022
Treatment Effects in Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale-ReplyDavid M Kent, Jeffrey L Saver, David E Thaler
Annals of Internal Medicine|May 5, 2015
Pharmacologic interventions for knee osteoarthritisRaveendhara R Bannuru, David M Kent, Timothy E McAlindon
Trials|May 24, 2008
Competing risk and heterogeneity of treatment effect in clinical trialsDavid M Kent, Alawi Alsheikh-Ali, Rodney A Hayward
Pageof 27